Could a common arthritis drug help black patients with kidney disease?
NCT ID NCT05237388
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether baricitinib, a drug used for arthritis, can safely reduce high protein levels in the urine of African American adults with a specific genetic form of kidney disease (APOL1). Eight participants took the drug to see if it lowered their urine protein and protected kidney function. The goal was to find a new treatment option for this serious condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APOL1-ASSOCIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Research at Pickett Road
Durham, North Carolina, 27705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new graft keep dialysis access working longer?
- Can a common gout pill shield hearts in kidney disease?
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a new drug combo shield young hearts from transplant complications?